| Document |
Document Title |
|
WO/2024/099269A1 |
Provided are following compound (I) or a pharmaceutically acceptable salt, ester, optical isomer, tautomer, stereoisomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite, chelate, complex, inclusion compound or prodrug ...
|
|
WO/2024/102999A2 |
Disclosed herein are small molecules that effectively block the interaction of SARS-CoV-2 Spike protein with ACE2. Also disclosed are methods for treating viral infections that involve entry via endocytic pathways. In one aspect, the sma...
|
|
WO/2024/099435A1 |
The present invention provides a compound represented by formula I, and a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof. As a TEAD inhibitor, the compound can significantly inhibi...
|
|
WO/2024/073282A3 |
Disclosed herein are amino bicyclic nitrogen heterocyclic ring system compounds which inhibit nuclear receptor-binding SET domain proteins (NSD's), such as 6-amino-9H-purin-9-yl, imidazo[2,1-f][1,2,4]triazin-4-amine, 4-amino pyrazolo[1,5...
|
|
WO/2024/098735A1 |
The present application belongs to the technical field of organic electroluminescence, and relates to an organic compound, and an organic electroluminescent apparatus and an electronic device using same. The organic compound has a struct...
|
|
WO/2024/102600A1 |
The present invention provides a method for preparing a compound of Formula D: wherein each R1 is independently halogen, nitro, SF5, N(C1-C8 alkyI)(C1-C8 alkyl), C(=S)N(C1-C8 alkyl )(C1-C8 alkyl), SO2N(C1-C8 alkyl)(C1-C8 alkyl), OSO2(C1-...
|
|
WO/2024/100578A1 |
The purity, crystallization, and granulation of hexamethylenetetramine, which is a crystalline heterocyclic organic compound, were improved by making changes in feed and equipment to increase the scope of application and use in sensitive...
|
|
WO/2024/100218A1 |
The present invention relates to method of purifying a compound of formula (IV-F) or a stereoisomer, racemic mixture, pharmaceutically acceptable salt, hydrate, or solvate thereof which contains C1-4 alkyl sulfonate as a leaving group. T...
|
|
WO/2024/099434A1 |
The present disclosure relates to a cucurbituril compound and the medical use thereof. Specifically, the present disclosure relates to a compound as shown in formula (I), a pharmaceutically acceptable salt thereof, a preparation method t...
|
|
WO/2024/099386A1 |
The present application relates to the field of pharmaceutical chemistry, relates to a fused bicyclic compound, and in particular relates to a compound represented by formula (II), a stereoisomer or a pharmaceutically acceptable salt the...
|
|
WO/2024/076614A3 |
The present disclosure provides pyrazolo[1,5-a]pyrimidine compounds and compositions comprising the same which inhibit IRAK and/or FLT3. The present disclosure further provides methods of using the pyrazolo[1,5-a]pyrimidine compounds to ...
|
|
WO/2024/102026A1 |
This invention relates to organic chemistry, pharmacology, medicine, namely the invention relates to compounds for use in inhibiting the activity of human cytochrome 11B2 (CYP11B2) and their use in the treatment and/or prevention of vari...
|
|
WO/2024/099416A1 |
The present invention relates to a fused tricyclic PARP1 inhibitor, a preparation method therefor, and a use thereof. In particular, the present invention relates to a compound capable of inhibiting poly ADP-ribose polymerase activity, a...
|
|
WO/2024/099898A1 |
The invention relates to substituted bi- and tricycles of the general formula (I),and the use of the compounds of the present invention as inhibitorsof HSET for the treatment and/or prevention of hyperproliferative diseases and disorders...
|
|
WO/2024/099398A1 |
Disclosed in the present invention are a class of sulfonamide compounds containing an ortho-fused heterocycle and the use thereof, and specifically disclosed is a compound of formula (II), a stereoisomer or a pharmaceutically acceptable ...
|
|
WO/2024/099382A1 |
The present disclosure relates to salts and solid forms of a compound that modulates APJ receptor activity, and their use as a therapeutic agent for treating diseases disorders, or conditions associated with repressed or impaired APJ rec...
|
|
WO/2024/099396A1 |
A ruxolitinib crystal and a pharmaceutical composition thereof. Specifically, provided are a ruxolitinib dihydrate crystal and a preparation method therefor. Further provided are a ruxolitinib free base in amorphous form and a preparatio...
|
|
WO/2024/042147A3 |
The invention relates to novel compounds having the general formula (I) wherein the substituents R1, R2, R3, R4 and X1 are as defined above, composition including the compounds and methods of using the compounds.
|
|
WO/2024/102849A1 |
The present disclosure provides certain bifunctional compounds that cause degradation of Cyclin-dependent kinase 2 (CDK2) via ubiquitin proteasome pathway and are therefore useful for the treatment of diseases mediated by CDK2. Also prov...
|
|
WO/2024/100115A1 |
A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.
|
|
WO/2024/102752A1 |
(I) or a stereoisomer or salt (e.g., pharmaceutically acceptable salt) thereof, wherein R1a, R1b, R2, R3a, R3b, R4a, R4b, R5a, Z, X, and m are as defined herein. Use of the compounds as a component of a pharmaceutical compositions and me...
|
|
WO/2024/102886A1 |
Disclosed are compounds of Formulas (I): (I) or a salt thereof, wherein R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using such compounds as inhibitors of TLR9, and pharmaceutical compositions comprising such comp...
|
|
WO/2024/103010A1 |
Compounds of Formula (I) or their pharmaceutically acceptable salts can inhibit the G12C, G12D, G12V, and/or G13D mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for trea...
|
|
WO/2023/138662A9 |
Disclosed are a series of benzopyrimidine compounds and a use thereof, and specifically disclosed are compounds represented by formula (II) and pharmaceutically acceptable salts thereof.
|
|
WO/2024/102970A1 |
Provided herein are heterobifunctional degrader compounds that bind with Spleen Tyrosine Kinase (SYK) and E3 ubiquitin ligase. Also provided are methods of treating a subject by administering a therapeutically effective amount of a pharm...
|
|
WO/2024/094170A1 |
Disclosed are an inhibitor compound of ubiquitin-specific protease 1 and a use thereof. The inhibitor compound specifically relates to a compound represented by formula (I) or an enantiomer, a diastereomer, a racemate, a tautomer, a ster...
|
|
WO/2024/094150A1 |
Described herein are NOD-like receptor protein 3 (NLRP3) inflammasome inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder ass...
|
|
WO/2024/097296A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2024/095964A1 |
The present invention addresses the problem of developing an antibody-drug complex containing a TLR7/8 dual agonist compound or a salt thereof to provide a pharmaceutical composition used for the prevention or treatment of various types ...
|
|
WO/2024/094566A1 |
The present invention relates to compounds of formula (I) as well as to their use as organic doping agent, as transport layer as absorbing layer, as charge injection layer, as organic semiconductor itself, organic semiconductive matrix m...
|
|
WO/2024/097989A1 |
The present disclosure relates to protein degradation inducing compounds for proto-oncogene tyrosine-protein kinase receptor (RET), which may be either wild type RET or a mutant form of RET useful in the treatment of diseases and disorde...
|
|
WO/2024/097805A1 |
Disclosed are substituted, heterocycle compounds. The substituted heterocycles disclosed herein are shown to be useful in activating necroptosis by activation of MLKL and may be utilized as therapeutics for treating cancer and cell proli...
|
|
WO/2024/094185A1 |
The present invention belongs to the technical field of medicine, relates to an NLRP3 inflammasome inhibitor and a use thereof, and specifically relates to a compound represented by a general formula (A') or a pharmaceutically acceptable...
|
|
WO/2024/097228A1 |
The present disclosure provides compounds of Formula (I), Formula (II), and Formula (III), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, or prodrugs thereof. The provided compounds may be kinase (e....
|
|
WO/2024/096093A1 |
The present invention provides a compound that has excellent control effects on harmful arthropods. Compounds represented by formula (I) (the meanings of the symbols of which are described in the description) or N-oxides thereof have exc...
|
|
WO/2024/097172A1 |
The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3‑kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): (I) or pharmaceut...
|
|
WO/2024/097972A2 |
The present invention describes compounds that inhbits GIT1. The invention further describes compositions containing these GIT1 inhibitors, as well as methods and kits using these GIT1 inhbitors to treat various medical conditions. Medic...
|
|
WO/2024/095177A1 |
The present disclosure provides a manganese bifunctional chelating agent conjugation platform for targeted MR imaging. The platform includes an MRI-active manganese porphyrin (MnP) compound connected to a linker which in turn is connecte...
|
|
WO/2024/095133A1 |
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful a...
|
|
WO/2024/093233A1 |
Disclosed herein are alkenyl-terminated tetraarylmetalloporphyrin compounds comprising an ethylene glycol unit, a preparation method therefor, and use thereof. The preparation method for the alkenyl-terminated tetraarylmetalloporphyrin c...
|
|
WO/2024/092420A1 |
A preparation method for a compound VI, the compound VI having a fluorotertiary carbon chiral center and an azaquaternary carbon chiral center, making the compound difficult to synthesize. The preparation method provided by the present a...
|
|
WO/2024/097436A1 |
Compounds for modulating the activity and/or the expression of 5-aminolevulinic acid synthase (ALAS) affecting biological functions. In part, novel compounds and pharmaceutically acceptable salts and in part, methods for preparing the no...
|
|
WO/2024/097559A1 |
The present invention is directed to inhibitors of Kirsten rat sarcoma virus (KRAS) oncoproteins, and more particularly to certain 1,5-napthyridine derivatives of Formula I: as well as compositions comprising Formula I and methods of usi...
|
|
WO/2024/094963A1 |
Provided are 2-amino-pyrido[2,3-d]pyrimidin-7(8H)-one and 7- amino-l-pyrimido[4,5-d]pyrimidin-2(lH)-one derivatives of the Formula (I), and salts, hydrates and solvates thereof. The compounds are inhibitors of EGFR, including mutated for...
|
|
WO/2024/094152A1 |
The present invention relates to a spiro compound, and a preparation method and use thereof. The spiro compound is as shown in formula I, has 3CL protease inhibitory activity, can effectively inhibit RNA virus replication of protein comp...
|
|
WO/2024/097775A1 |
The disclosure relates to anti-cancer compounds derived from nuclear receptor binders, such as nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
|
|
WO/2024/097980A1 |
The present disclosure relates to protein binding compounds for proto-oncogene tyrosine-protein kinase receptor (RET), which may be either wild type RET or a mutant form of RET that are useful in the treatment of diseases and disorders m...
|
|
WO/2024/088189A1 |
The present disclosure provides a compound of formula (I), a pharmaceutical composition thereof, and a use thereof in treating and/or preventing diseases or disorders related to CDK9 kinase activity.
|
|
WO/2024/088237A1 |
Compounds of a general formula, the use thereof, and an organic electroluminescent device containing same. The compounds have structures represented by formula (1), wherein the dotted line represents ring A being an optional structure; w...
|
|
WO/2024/088311A1 |
The present invention belongs to the technical field of medicine, and specifically relates to a crystal form of an imidazopyrazine derivative represented by formula (I), a preparation method therefor and a use thereof.
|
